glp 1 agonist vs analog Frontiers Multifaceted Roles of GLP-1 and

Therefore, DPP-4 inhibitors, like GLP-1R agonists, may be a potential drug for the treatment of AD

A total of 3286 patients had taken a GLP-1 RA and 1692 had taken an SGLT2i at some point in time

These studies indicate an increased risk for serious, potentially life-altering conditions such as gastroparesis, blood clots, and vision loss associated with the use of the drug

Despite the extensive evidence supporting the beneficial effects of GLP-1RAs on the central nervous system (CNS), emerging studies have raised concerns about potential adverse effects

Currently, in vitro studies on peptide-mediated DDIs, which would provide better in vitro to in vivo extrapolation, remain poorly established